Purpose To determine prognostic factors and overall survival (OS) in therapy-related
myeloid neoplasm (t-MN) of patients after receiving peptide receptor radionuclide therapy …

Background Therapy related myeloid neoplasms (t-MN) occur due to direct mutational
events of chemotherapeutic agents and radiotherapy. Disease latency, mutational events …

DNA topoisomerase II (TOP2) plays a critical role in many processes such as replication and
transcription, where it resolves DNA structures and relieves torsional stress. Recent …

An initiating DNA double strand break (DSB) event precedes the formation of cancer‐driven
chromosomal abnormalities, such as gene rearrangements. Therefore, measuring DNA …

Therapy-related myelodysplastic syndrome (t-MDS), defined as MDS occurring after
previous exposure to chemotherapy or radiotherapy, constitutes 10% to 20% of all MDS …

Introduction Therapy‐related myelodysplastic syndrome and acute myeloid leukemia (t‐
MDS/AML) are defined as complications of previous cytotoxic therapy. Azacitidine (AZA), a …

Myeloid neoplasms postcytotoxic therapy (MN-pCT) in children represent a heterogeneous
group of neoplasms which primarily arise following exposure to alkylating agents …

Acute promyelocytic leukemia (APL) has become a highly curable malignant disease after
the introduction of all transretinoic acid (ATRA) to chemotherapy treatment. However, the risk …

Objective To quantify incident haematological malignancies identified exclusively through
the laboratory information system and to measure the impact of that source on the sensitivity …

We analyzed treatment outcomes and prognostic factors in adult patients with therapy-
related myeloid neoplasms (t-MNs) to select patients who would be benefited by active …